(Q74601842)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

main subject

phase II clinical trial

1 reference

1 reference

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Françoise Brun-Vézinet

3

object named as

F Brun-Vezinet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

A M Been-Tiktak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

C A Boucher

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

V Joly

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J W Mulder

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J Jost

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

D A Cooper

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M Moroni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J M Gatell

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S Staszewski

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R Colebunders

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G J Stewart

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

D A Hawkins

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M A Johnson

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J M Parkin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

D H Kennedy

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J C Borleffs

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 January 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Antimicrobial Agents

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

13-21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Molecular targets for AIDS therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Rapid and simple method for purification of nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Cutaneous disease and drug reactions in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Adverse reactions to co-trimoxazole in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Adverse reactions to co-trimoxazole in HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

Successful treatment of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in hypersensitive AIDS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900082-X

7 January 2021

10.1016/S0924-8579(98)00082-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10075273%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference